Abstract:

Objective To investigate the clinical efficacy of peptide receptor radionuclide therapy （PRRT）in patients with recurrent neuroendocrine tumors （NETs） after liver transplantation. Methods A retrospective analysis was conducted on the clinical data of 5 patients with recurrent NETs after liver transplantation who underwent PRRT from April 2023 to May 2024 in Tianjin First Central Hospital. Adverse reactions and treatment efficacy were evaluated. Results The median follow-up was 15.6 months. Among the patients，1 achieved partial response （PR），3 had stable disease （SD）， and 1 experienced progressive disease （PD）. Liver function remained stable during treatment， and no rejection reactions occurred. Grade 3 neutropenia was observed in 2 cases， while grade 2 neutropenia occurred in 3 cases. Symptomatic treatment alleviated the condition in 4 cases， but 1 case had persistent severe neutropenia， leading to treatment discontinuation. Grade 1 ～ 2 proteinuria was observed in 2 cases. Conclusion PRRT is safe and effective for patients with recurrent NETs after liver transplantation. The main side effect is neutropenia， and PRRT can be considered as one of the multimodal treatment options. 

Key words:

Neuroendocrine tumors； , Liver transplantation； , Recurrence； , PRRT； , Efficacy

摘要：

目的 探讨神经内分泌肿瘤（neuroendocrine tumors，NETs）肝移植术后复发者行肽受体放射性核素疗法（peptide receptor radionuclide therapy，PRRT）的临床疗效。方法 回顾性分析 2023 年 4 月至2024 年 5 月在天津市第一中心医院接受 PRRT 治疗的 5 例 NETs 肝移植复发受者临床资料，进行不良反应分析及疗效评估。结果 中位随访时间为 15.6 个月，1 例为部分缓解（particial response，PR），3 例为疾病稳定（stabledisease，SD），1 例为进展（progressive disease，PD）。治疗期间肝功能稳定，无排斥反应发生。3 级粒细胞减少 2 例，2 级粒细胞减少 3 例，4 例经对症治疗后可缓解，1 例持续严重粒细胞减少被迫中止治疗。2 例出现1 ～ 2 级蛋白尿。结论 NETs 肝移植术后复发受者行 PRRT 治疗是安全和有效的，主要不良反应为粒细胞减少，PRRT 可作为多模式治疗选择之一。

关键词:

神经内分泌肿瘤 , 肝移植 , 复发 , 肽受体放射性核素疗法 , 疗效